CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies.

Abstract

The current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the heterogeneity of tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematological disorders. Consequently, new treatment strategies are necessary to improve clinical outcomes. Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological malignancies. In this review, through a representative case study, we summarize the current experience of CAR T-cell therapy, the management of common side effects, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell therapy.

• Authors: Jian-Qing Mi, Jie Xu, Jianfeng Zhou, Weili Zhao, Zhu Chen, J Joseph Melenhorst, Saijuan Chen
• Journal: Frontiers of medicine (Front Med) Vol. 15 Issue 6 Pg. 783-804 (Dec 2021) ISSN: 2095-0225 [Electronic] China
• PMID: 34921673 (Publication Type: Journal Article, Review)
• Copyright: © 2021. Higher Education Press.

Chemical References

• Receptors, Chimeric Antigen

Topics

• Hematologic Neoplasms (therapy)
• Humans
• Immunotherapy (adverse effects)
• Neoplasms
• Receptors, Chimeric Antigen
• T-Lymphocytes